Jump Financial, LLC Dynavax Technologies Corp Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Oct 21, 2024	SELL	$9.85 - $13.17 $949,559 - $1.27 Million	-96,402 Reduced 90.31%	10,339 $133,000
Q2 2023 Aug 07, 2023	SELL	$9.85 - $13.17 $949,559 - $1.27 Million	-96,402 Reduced 90.31%	10,339 $133,000
Q1 2023 Oct 21, 2024	BUY	$9.44 - $11.88 $1.01 Million - $1.27 Million	106,741 New	106,741 $1.05 Million
Q1 2023 May 03, 2023	BUY	$9.44 - $11.88 $1.01 Million - $1.27 Million	106,741 New	106,741 $1.05 Million
Q2 2022 Aug 09, 2022	SELL	$7.45 - $12.83 $210,835 - $363,089	-28,300 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$9.75 - $14.44 $955,851 - $1.42 Million	-98,036 Reduced 77.6%	28,300 $307,000
Q4 2021 Feb 10, 2022	SELL	$13.17 - $20.94 $360,159 - $572,646	-27,347 Reduced 17.79%	126,336 $1.78 Million
Q3 2021 Nov 12, 2021	BUY	$9.16 - $19.83 $303,296 - $656,591	33,111 Added 27.46%	153,683 $2.95 Million
Q2 2021 Aug 13, 2021	BUY	$7.25 - $10.99 $874,147 - $1.33 Million	120,572 New	120,572 $1.19 Million
Q4 2020 Feb 12, 2021	SELL	$3.73 - $5.6 $577,844 - $867,540	-154,918 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.32 - $11.7 $669,245 - $1.81 Million	154,918 New	154,918 $669,000

257

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.